Intelligence Brief

Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally… Read full dossier